Indications |
Oral Movement disorders Adult: Initially 12.5 mg bid, increased gradually to 12.5-25 mg tid. Max: 200mg daily. If no improvement at max dose for 7 days, drug unlikely to be of benefit. Elderly: Initially 12.5 mg daily, increased gradually. Oral Moderate to severe tardive dyskinesia Adult: Initially 12.5 mg daily increased gradually according to response. |
Contraindications |
Lactation. |
Warnings / Precautions |
May exacerbate symptoms of parkinsonism. Caution to be exercised when driving or performing skilled tasks. Pregnancy. |
Adverse Reactions |
Drowsiness, extrapyramidal symptoms, parkinsonism, depression, orthostatic hypotension, GI disturbances. Potentially Fatal: Neuroleptic malignant syndrome (NMS). |
Overdose Reactions |
Drowsiness, sweating, hypotension, and hypothermia. Supportive and symptomatic treatment. |
Drug Interactions |
Tetrabenazine should not be given with or within 14 days of discontinuation of MAOI therapy. Blocks action of reserpine. Decreases effects of levodopa and worsen parkinsonism. Increased risk of extrapyramidal side effects when given with amantadine, metoclopramide, antipsychotics. See Below for More tetrabenazine Drug Interactions |
Mechanism of Actions |
Tetrabenazine act by depleting nerve endings of dopamine in the brain and is used to control movement disorders. Absorption: Poorly and erratically absorbed from the GIT (oral). Metabolism: Extensive hepatic first-pass metabolism reduced to hydroxytetrabenazine. Excretion: Via urine (as metabolites). |
Administration |
May be taken with or without food. |
Storage Conditions |
Oral: Store below 30°C. |
ATC Classification |
N07XX06 - tetrabenazine ; Belongs to the class of other nervous system drugs. |
Storage |
Oral: Store below 30°C. |
Available As |
|
Tetrabenazine
Post Review about Tetrabenazine Click here to cancel reply.
Tetrabenazine Containing Brands
Tetrabenazine is used in following diseases
Drug - Drug Interactions of Tetrabenazine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.